Arrowhead Pharmaceuticals, Inc. shares have underperformed despite a lucrative $1.1bn+ licensing deal with Sarepta, providing significant upfront and milestone payments. The Sarepta partnership covers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results